Revenue Breakdown
Composition ()
No data
Revenue Streams
Bionano Genomics Inc (BNGO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Consumables, accounting for 48.7% of total sales, equivalent to $3.28M. Other significant revenue streams include Software and Instruments. Understanding this composition is critical for investors evaluating how BNGO navigates market cycles within the Advanced Medical Equipment & Technology industry.
Profitability & Margins
Evaluating the bottom line, Bionano Genomics Inc maintains a gross margin of 45.74%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -115.90%, while the net margin is -115.42%. These profitability ratios, combined with a Return on Equity (ROE) of -78.22%, provide a clear picture of how effectively BNGO converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, BNGO competes directly with industry leaders such as LGVN and CMMB. With a market capitalization of $11.40M, it holds a significant position in the sector. When comparing efficiency, BNGO's gross margin of 45.74% stands against LGVN's 91.24% and CMMB's N/A. Such benchmarking helps identify whether Bionano Genomics Inc is trading at a premium or discount relative to its financial performance.
